[The State Food and Drug Administration approves the world’s first factor XI inhibitor to be launched in China] October 26th, today, the State Food and Drug Administration approved the world’s first factor XI inhibitor to be launched in China. It is understood that this drug is a drug with a new mechanism and a new target, and can be used in combination with currently marketed standard treatments for stroke to prevent the recurrence of stroke in patients. It is of great value for the long-term management of stroke. It is understood that this drug is also the first globally approved secondary prevention anticoagulant drug for non-cardioembolic ischemic stroke and high-risk transient ischemic attack. The potential risk of bleeding from a mechanism of action perspective is lower than that of marketed anticoagulants.